Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastric, or Gastroesophageal Junction Adenocarcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT00683787
What this trial is testing

Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

Who this might be right for
Gastric Cancer
Roswell Park Cancer Institute 8
Testing effectiveness (Phase 2)UnknownNCT03959293
What this trial is testing

Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastric Cancer
Federation Francophone de Cancerologie Digestive 107
Large-scale testing (Phase 3)Not Yet RecruitingNCT07449780
What this trial is testing

AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric / Gastroesophageal Junction Adenocarcinoma
Akeso 422
Early research (Phase 1)Looking for participantsNCT04900818
What this trial is testing

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

Who this might be right for
Solid TumorAdvanced CancerMetastatic Cancer+5 more
I-Mab Biopharma US Limited 330
Large-scale testing (Phase 3)Active Not RecruitingNCT05180734
What this trial is testing

PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Who this might be right for
Gastric or Esophagogastric Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd. 878
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06118658
What this trial is testing

Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations

Who this might be right for
GastricColorectal Adenocarcinoma
China Medical University, China 30
Large-scale testing (Phase 3)Looking for participantsNCT07284134
What this trial is testing

JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.

Who this might be right for
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd. 560
Testing effectiveness (Phase 2)UnknownNCT05625737
What this trial is testing

Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

Who this might be right for
Stomach Neoplasms
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 29
Not applicableApproved For MarketingNCT02307812
What this trial is testing

Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Eli Lilly and Company
Early research (Phase 1)UnknownNCT05315830
What this trial is testing

HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric

Who this might be right for
Adenocarcinoma - GEJAdenocarcinoma of the Stomach
The First Affiliated Hospital of Bengbu Medical University 10
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06942767
What this trial is testing

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Qilu Pharmaceutical Co., Ltd. 100
Large-scale testing (Phase 3)Study completedNCT05052801
What this trial is testing

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Amgen 547
Testing effectiveness (Phase 2)Study completedNCT00061932
What this trial is testing

Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionDiffuse Adenocarcinoma of the StomachIntestinal Adenocarcinoma of the Stomach+5 more
National Cancer Institute (NCI) 41
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07609667
What this trial is testing

SKB315 in Combination Therapy in Patients With Advanced or Metastatic GC/ GEJ Adenocarcinoma

Who this might be right for
Gastroesophageal Junction Adenocarcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 80
Early research (Phase 1)Study completedNCT02572687
What this trial is testing

Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaNon-Small Cell Lung Cancer+1 more
Eli Lilly and Company 85
Large-scale testing (Phase 3)Looking for participantsNCT06221748
What this trial is testing

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd. 90
Testing effectiveness (Phase 2)Active Not RecruitingNCT06939452
What this trial is testing

A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression

Who this might be right for
Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Yongxu Jia 37
Large-scale testing (Phase 3)Not Yet RecruitingNCT07677293
What this trial is testing

Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases

Who this might be right for
Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Peking University 332
Testing effectiveness (Phase 2)Study completedNCT02096666
What this trial is testing

A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects

Who this might be right for
Stomach Neoplasms
Amgen 11
Large-scale testing (Phase 3)Active Not RecruitingNCT04208347
What this trial is testing

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Who this might be right for
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Ruijin Hospital 580
Next Page